Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.

including the popular weight-loss drug Mounjaro. Eli Lilly said the investment will create 3,000 high-skilled positions and approximately 10,000 construction jobs. Eli Lilly has unveiled plans to ...

Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in ... Eli Lilly first launched its diabetes medication Mounjaro in 2022. A year later, it started ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. Developing a new ...

The new investments aren't solely dedicated to Eli Lilly's current and future obesity and diabetes treatments. The company is charting its future beyond Zepbound and Mounjaro, with hopes to ...